| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
COX
Aspirin (acetylsalicylic acid) and aluminum. Aspirin Aluminum is an intermolecular compound of aspirin and aluminum that delivers the anti-inflammatory, analgesic, and antipyretic effects of aspirin while reducing gastrointestinal side effects. The aluminum component provides a protective effect on the gastric mucosa. |
|---|---|
| ln Vitro |
Aspirin Aluminum inhibits gastrointestinal mucosal disorders induced by NSAIDs. It retains the pharmacological activity of aspirin (cyclooxygenase inhibition, anti-inflammatory, analgesic, antipyretic effects) while the aluminum component provides gastroprotective properties. The compound reduces NSAID-induced gastric damage.
|
| ln Vivo |
In vivo, Aspirin Aluminum would be expected to demonstrate anti-inflammatory, analgesic, and antipyretic effects similar to aspirin, with improved gastrointestinal tolerability. The compound's aluminum component provides protection against gastric mucosal injury. Efficacy would be assessed in models of inflammation, pain, and fever, with gastrointestinal safety as a key endpoint.
|
| Enzyme Assay |
Aspirin Aluminum is characterized by its chemical structure and purity rather than enzymatic activity. The compound's aspirin component inhibits cyclooxygenase (COX-1 and COX-2) activity. COX inhibition assays measure the conversion of arachidonic acid to prostaglandins in the presence of test compound. IC₅0 values are calculated from dose-response curves.
|
| Cell Assay |
Cells (e.g., gastric epithelial cells, macrophages) are treated with Aspirin Aluminum at various concentrations. COX activity and prostaglandin production are measured by ELISA. Cytotoxicity is assessed using MTT or LDH release assays. Gastroprotective effects are evaluated by measuring inflammatory markers and mucosal integrity in gastric cell models.
|
| Animal Protocol |
Animal models of inflammation (e.g., carrageenan-induced paw edema, adjuvant-induced arthritis) and pain (e.g., acetic acid-induced writhing, tail-flick test) are used to assess efficacy. Gastrointestinal safety is evaluated in models of NSAID-induced gastric ulceration. Animals are administered Aspirin Aluminum orally, and endpoints include inflammation reduction, pain relief, and gastric mucosal integrity.
|
| ADME/Pharmacokinetics |
Aspirin Aluminum has a molecular weight of 402.29 g/mol and formula C1₈H1₅AlO₉. The compound is an aluminum-containing aspirin derivative. Standard PK parameters (absorption, distribution, metabolism, excretion) would be determined in rodent studies. The aluminum component may influence absorption and tissue distribution compared to aspirin alone.
|
| Toxicity/Toxicokinetics |
Toxicology data for Aspirin Aluminum are limited. As an aluminum-containing compound, potential aluminum-related toxicities (e.g., neurotoxicity, renal toxicity) would need to be evaluated. Standard preclinical safety assessment would include repeat-dose toxicology studies in rodents to determine maximum tolerated dose and identify potential target organs.
|
| References | |
| Additional Infomation |
Aspirin Aluminum is a pharmaceutical compound for pain, fever, and inflammation management. It is not widely approved in all regions. The compound is disclosed in patent WO 2010064441 A1. It is designed to provide the therapeutic benefits of aspirin with reduced gastrointestinal side effects, making it suitable for sensitive or ulcer-prone patients.
|
| Molecular Formula |
2[C9H7O4-].AL+3.HO-
|
|---|---|
| Molecular Weight |
402.2878
|
| CAS # |
23413-80-1
|
| Related CAS # |
Aspirin;50-78-2
|
| PubChem CID |
3032790
|
| Appearance |
Typically exists as White to off-white solid at room temperature
|
| Boiling Point |
321.4ºC at 760mmHg
|
| Flash Point |
131.1ºC
|
| LogP |
3.699
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
206
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[O-][Al+3]12(O=C(OC3C=CC=CC=3C(=O)[O-]1)C)O=C(OC1C=CC=CC=1C(=O)[O-]2)C
|
| Synonyms |
Aluminum diacetylsalicylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~6 mg/mL (~14.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4858 mL | 12.4288 mL | 24.8577 mL | |
| 5 mM | 0.4972 mL | 2.4858 mL | 4.9715 mL | |
| 10 mM | 0.2486 mL | 1.2429 mL | 2.4858 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
